Melanoma
Iovance submits EU marketing authorization for lifileucel for advanced melanoma
Iovance Biotherapeutics has submitted a marketing authorization application to the European Medicines Agency for lifileucel to treat advanced melanoma, the company announced in a press release.
Fox Chase Cancer Center appoints chair of surgery
Jeffrey M. Farma, MD, FACS, has been appointed chair of surgery at Fox Chase Cancer Center.
Neoadjuvant immunotherapy ‘the new standard’ for resectable stage III melanoma
CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial presented at ASCO Annual Meeting showed.
‘There may be a role’ for frontline lifileucel plus pembrolizumab in advanced melanoma
CHICAGO — A front-line treatment regimen including lifileucel and pembrolizumab produced ongoing durable responses in some patients with unresectable or metastatic melanoma, according to findings presented at ASCO Annual Meeting.
Targeted therapy combination extends survival in BRAF-mutant melanoma
CHICAGO — Adjuvant dabrafenib plus trametinib reduced mortality risk for adults with resected stage III BRAF V600-mutant melanoma, according to final results of the randomized phase 3 COMBI-AD trial.
Vibostolimab, pembrolizumab coformulation trial discontinued for resected high-risk melanoma
Merck has discontinued the vibostolimab and pembrolizumab coformulation arm of its phase 3 trial for the adjuvant treatment of patients with resected high-risk melanoma, the company announced in a press release.
Not all treatments created equal: Identifying barriers to immunotherapy for melanoma
Immunotherapy is a life-saving treatment for melanoma, but not all individuals have access to this treatment, according to a study.
Melanoma cases rise despite unchanging mortality rate
Researchers found an inexplicable rise of melanoma incidences despite an unchanging mortality rate, according to a study.
Melanoma Monday: Military members at risk; sleep apnea may worsen outcomes
Today is Melanoma Monday. The annual observance is intended to raise awareness about causes and symptoms of melanoma, the deadliest form of skin cancer.
Alpha-9 Oncology doses first subject in phase 1 study for new melanoma diagnostic agent
The first participant has been dosed in the phase 1 study evaluating Ga-A9-3202 for locally advanced or metastatic melanoma imaging, Alpha-9 Oncology announced in a press release.